Q & A: Dr. Thomas Rando on preventing age-related diseases and turning discoveries into cures
For Dr. Thomas Rando, the path to becoming a physician-scientist began with something that hedidn ’t learn in high school biology.After one class that touched on the connections between neurons and muscle fibers, Rando took it upon to himself to find all the information he could about how cells communicate through electrical signals.Soon, he began pursuing that interest at Harvard University, where he completed his undergraduate work, a doctorate in cell and developmental biology and his medical degree.Rando joined the neurology faculty at the Stanford University School of Medicine in 1995.There, he founded a clinic to t...
Source: UCLA Newsroom: Health Sciences - December 10, 2021 Category: Universities & Medical Training Source Type: news
Fern ández-Hernando named Anthony N. Brady Professor of Comparative Medicine
Carlos Fern ández-Hernando’s work combines cell biology, genetics, and mouse models to study lipid metabolism and cardiovascular-related disorders. (Source: Yale Science and Health News)
Source: Yale Science and Health News - December 9, 2021 Category: Universities & Medical Training Source Type: news
Brooke Gardner Probes the Cell's Peroxisomes
The University of California, Santa Barbara, cell biologist is investigating the formation and functions of the peroxisome, an organelle which exists in many copies in each cell and can be created,... (Source: The Scientist)
Source: The Scientist - December 1, 2021 Category: Science Tags: Magazine Issue Scientist to Watch Source Type: news
Reducing cell culture contamination with INTEGRA & #39;s versatile pipettes
INTEGRA Biosciences– a leading provider of high quality laboratory equipment– supplies a comprehensive range of liquid handling tools that are ideal for sterile cell biology workflows. (Source: The Scientist)
Source: The Scientist - November 23, 2021 Category: Science Tags: The Scientist The Marketplace Source Type: news
Company raises $55M to advance therapies for celiac, other autoimmune disorders
Biotech company Mozart Therapeutics has raised $55 million in Series A funding.
Mozart is targeting autoimmune and inflammatory diseases through a network of what are called CD8 regulatory T cells. The work is built on the research of T cell biology expert Mark M. Davis. Mozart said the Series A will help the company to progress its treatment to the clinic while advancing oth er programs as well.
"Mozart is doing something truly unique to change the treatment paradigm for patients with autoimmune… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 29, 2021 Category: Pharmaceuticals Authors: Rick Morgan Source Type: news
Company raises $55M to advance therapies for celiac, other autoimmune disorders
Biotech company Mozart Therapeutics has raised $55 million in Series A funding.
Mozart is targeting autoimmune and inflammatory diseases through a network of what are called CD8 regulatory T cells. The work is built on the research of T cell biology expert Mark M. Davis. Mozart said the Series A will help the company to progress its treatment to the clinic while advancing oth er programs as well.
"Mozart is doing something truly unique to change the treatment paradigm for patients with autoimmune… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 29, 2021 Category: Biotechnology Authors: Rick Morgan Source Type: news
IMPACT trial data shows clear benefit in using Roche's CINtec PLUS Cytology test for women who are at higher risk of developing cervical cancer
IMPACT trial data shows clear benefit in using Roche ' sCINtec PLUS Cytology test for women who are at higher risk of developing cervical cancer (Source: Roche Media News)
Source: Roche Media News - October 29, 2021 Category: Pharmaceuticals Source Type: news
IMPACT trial data shows clear benefit in using Roche's CINtec PLUS Cytology test for women who are at higher risk of developing cervical cancer
IMPACT trial data shows clear benefit in using Roche ' sCINtec PLUS Cytology test for women who are at higher risk of developing cervical cancer (Source: Roche Investor Update)
Source: Roche Investor Update - October 29, 2021 Category: Pharmaceuticals Source Type: news
Mozart Therapeutics raises $55M to advance disease therapies
Seattle-based biotech company Mozart Therapeutics has raised $55 million in Series A funding.
Mozart is targeting autoimmune and inflammatory diseases through a network of what are called CD8 regulatory T cells. The work is built on the research of T cell biology expert Mark M. Davis. Mozart said the Series A will help the company to progress its treatment to the clinic while advancing oth er programs as well.
"Mozart is doing something truly unique to change the treatment paradigm for patients… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 26, 2021 Category: American Health Authors: Rick Morgan Source Type: news
Neuromics' FBS and National Cancer Institutes
Best Price and Performance I was honored to work with Jessey at National Cancer Institute (NCI).The were determining whether to change partners. According to Jessey, there were 24 lab PIs who would be supplied with the winner ' s FBS Although we proved competitive, we were not selected.The study was uconducted with only premium grade FBS (most expensive). We are announcing a new Preferred FBS this Monday 10/25. It works well for supplementing define media and works great for most human primary sells. And works fabulous for human and animal cancer cells.Interested in learning more? Contact me at pshuster@neuromic...
Source: Neuromics - October 23, 2021 Category: Neuroscience Tags: Bone Cancer Pain Cancer Associated Fibroblasts cell biology FBS Fetal Bovine Serum national cancer Institute Source Type: news
Cell biology startup Transition Bio hires first CEO
Nearly a year after its public launching, Transition Bio has its first CEO in Gregory Miller, who was the second employee at another local startup, neurodegenerative disease-focused Atalanta Therapeutics.
Miller has been working with Transition for about the past five months as a strategic advisor. When he joined last month, it was the first time he had stepped into the corner office. Miller was chief business officer at Atalanta as well as Waltham-based Visterra Inc. before that. He also held… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 13, 2021 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news
miRNA Expression in LBC Samples for Lung Cancer Diagnosis miRNA Expression in LBC Samples for Lung Cancer Diagnosis
Might the analysis of miRNA expression in liquid-based cytology samples collected by bronchoscopy be useful for primary lung cancer diagnosis?American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 13, 2021 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news
UCLA Broad Stem Cell Research Center receives $5 million CIRM grant for research training program
TheEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLAhas been awarded $5 million by the California Institute for Regenerative Medicine, the state ’s stem cell agency, to train young scientists and physicians to become leaders in the stem cell and regenerative medicine field.The five-year grant will enable the center to expand its Stem Cell Training Program, which was established in 2006 and funded by CIRM until 2015, when the agency changed its funding priorities. Since then, the program has been sustained by philanthropy. With the passage of Proposition 14 last fall, however, CIRM has on...
Source: UCLA Newsroom: Health Sciences - September 23, 2021 Category: Universities & Medical Training Source Type: news
Quantum Dots Light Up The Brain
What are quantum dots and how are they being used to study neural cells and the brain? Scientists are looking at this nanotechnology to study cell biology, and someday, perhaps even as new clinical biomarkers and therapeutics. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 23, 2021 Category: Pharmaceuticals Authors: Gabriel A. Silva, Contributor Tags: Science /science Innovation /innovation Healthcare /healthcare Source Type: news
